FilingSEC EDGAR6-K
Evaxion Expands AI-Immunology Platform to Autoimmune Diseases
· SEC accepted
StageEarly-stage research
Filing content
The company has begun experimental testing of tolerogenic vaccine and autoantibody binder concepts for autoimmune diseases using its AI-ImmunologyTM platform, with initial data to be presented at PEGS Europe on November 18.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…